ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Bispecific Antibodies for Cancer Market Insights, Forecast to 2030
Published Date: December 2024
|
Report Code: QYRE-Auto-27I7070
Home | Market Reports | Health| Health Conditions| Cancer
Global Bispecific Antibodies for Cancer Market Insights Forecast to 2028
BUY CHAPTERS

Global Bispecific Antibodies for Cancer Market Insights, Forecast to 2030

Code: QYRE-Auto-27I7070
Report
December 2024
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Amgen Inc
Astella Pharma
Ben Kang Biopharmaceutical (Shenzhen)
Merus NV
Regeneron Pharmaceuticals

Bispecific Antibodies for Cancer Market

Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy.
The global Bispecific Antibodies for Cancer market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Bispecific Antibodies for Cancer is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Bispecific Antibodies for Cancer is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Bispecific Antibodies for Cancer is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key manufacturers of Bispecific Antibodies for Cancer include Amgen, Astella Pharma, Ben Kang Biopharmaceutical (Shenzhen), Merus and Regeneron Pharmaceuticals, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Covers:
This report presents an overview of global market for Bispecific Antibodies for Cancer, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Bispecific Antibodies for Cancer, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Bispecific Antibodies for Cancer, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Bispecific Antibodies for Cancer sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Bispecific Antibodies for Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Bispecific Antibodies for Cancer sales, projected growth trends, production technology, application and end-user industry.
Market Segmentation

Scope of Bispecific Antibodies for Cancer Market Report

Report Metric Details
Report Name Bispecific Antibodies for Cancer Market
Segment by Type
  • CD19/CD3
  • CD30/CD16A
Segment by Application
  • Hospital
  • Pharmaceutical Companies
  • Other
Segment by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Ben Kang Biopharmaceutical (Shenzhen), Merus, Regeneron Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Sales (consumption), revenue of Bispecific Antibodies for Cancer in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 3: Detailed analysis of Bispecific Antibodies for Cancer manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
  • Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bispecific Antibodies for Cancer sales, revenue, price, gross margin, and recent development, etc.
  • Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
  • Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 14: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Bispecific Antibodies for Cancer Market report?

Ans: The main players in the Bispecific Antibodies for Cancer Market are Ben Kang Biopharmaceutical (Shenzhen), Merus, Regeneron Pharmaceuticals

What are the Application segmentation covered in the Bispecific Antibodies for Cancer Market report?

Ans: The Applications covered in the Bispecific Antibodies for Cancer Market report are Hospital, Pharmaceutical Companies, Other

What are the Type segmentation covered in the Bispecific Antibodies for Cancer Market report?

Ans: The Types covered in the Bispecific Antibodies for Cancer Market report are CD19/CD3, CD30/CD16A

1 Study Coverage
1.1 Bispecific Antibodies for Cancer Product Introduction
1.2 Market by Type
1.2.1 Global Bispecific Antibodies for Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 CD19/CD3
1.2.3 CD30/CD16A
1.3 Market by Application
1.3.1 Global Bispecific Antibodies for Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Pharmaceutical Companies
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Bispecific Antibodies for Cancer Sales Estimates and Forecasts 2019-2030
2.2 Global Bispecific Antibodies for Cancer Revenue by Region
2.2.1 Global Bispecific Antibodies for Cancer Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Bispecific Antibodies for Cancer Revenue by Region (2019-2024)
2.2.3 Global Bispecific Antibodies for Cancer Revenue by Region (2025-2030)
2.2.4 Global Bispecific Antibodies for Cancer Revenue Market Share by Region (2019-2030)
2.3 Global Bispecific Antibodies for Cancer Sales Estimates and Forecasts 2019-2030
2.4 Global Bispecific Antibodies for Cancer Sales by Region
2.4.1 Global Bispecific Antibodies for Cancer Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Bispecific Antibodies for Cancer Sales by Region (2019-2024)
2.4.3 Global Bispecific Antibodies for Cancer Sales by Region (2025-2030)
2.4.4 Global Bispecific Antibodies for Cancer Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Bispecific Antibodies for Cancer Sales by Manufacturers
3.1.1 Global Bispecific Antibodies for Cancer Sales by Manufacturers (2019-2024)
3.1.2 Global Bispecific Antibodies for Cancer Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Bispecific Antibodies for Cancer in 2023
3.2 Global Bispecific Antibodies for Cancer Revenue by Manufacturers
3.2.1 Global Bispecific Antibodies for Cancer Revenue by Manufacturers (2019-2024)
3.2.2 Global Bispecific Antibodies for Cancer Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Bispecific Antibodies for Cancer Revenue in 2023
3.3 Global Key Players of Bispecific Antibodies for Cancer, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Bispecific Antibodies for Cancer Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Bispecific Antibodies for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Bispecific Antibodies for Cancer, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Bispecific Antibodies for Cancer, Product Offered and Application
3.8 Global Key Manufacturers of Bispecific Antibodies for Cancer, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Bispecific Antibodies for Cancer Sales by Type
4.1.1 Global Bispecific Antibodies for Cancer Historical Sales by Type (2019-2024)
4.1.2 Global Bispecific Antibodies for Cancer Forecasted Sales by Type (2025-2030)
4.1.3 Global Bispecific Antibodies for Cancer Sales Market Share by Type (2019-2030)
4.2 Global Bispecific Antibodies for Cancer Revenue by Type
4.2.1 Global Bispecific Antibodies for Cancer Historical Revenue by Type (2019-2024)
4.2.2 Global Bispecific Antibodies for Cancer Forecasted Revenue by Type (2025-2030)
4.2.3 Global Bispecific Antibodies for Cancer Revenue Market Share by Type (2019-2030)
4.3 Global Bispecific Antibodies for Cancer Price by Type
4.3.1 Global Bispecific Antibodies for Cancer Price by Type (2019-2024)
4.3.2 Global Bispecific Antibodies for Cancer Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Bispecific Antibodies for Cancer Sales by Application
5.1.1 Global Bispecific Antibodies for Cancer Historical Sales by Application (2019-2024)
5.1.2 Global Bispecific Antibodies for Cancer Forecasted Sales by Application (2025-2030)
5.1.3 Global Bispecific Antibodies for Cancer Sales Market Share by Application (2019-2030)
5.2 Global Bispecific Antibodies for Cancer Revenue by Application
5.2.1 Global Bispecific Antibodies for Cancer Historical Revenue by Application (2019-2024)
5.2.2 Global Bispecific Antibodies for Cancer Forecasted Revenue by Application (2025-2030)
5.2.3 Global Bispecific Antibodies for Cancer Revenue Market Share by Application (2019-2030)
5.3 Global Bispecific Antibodies for Cancer Price by Application
5.3.1 Global Bispecific Antibodies for Cancer Price by Application (2019-2024)
5.3.2 Global Bispecific Antibodies for Cancer Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Bispecific Antibodies for Cancer Market Size by Type
6.1.1 US & Canada Bispecific Antibodies for Cancer Sales by Type (2019-2030)
6.1.2 US & Canada Bispecific Antibodies for Cancer Revenue by Type (2019-2030)
6.2 US & Canada Bispecific Antibodies for Cancer Market Size by Application
6.2.1 US & Canada Bispecific Antibodies for Cancer Sales by Application (2019-2030)
6.2.2 US & Canada Bispecific Antibodies for Cancer Revenue by Application (2019-2030)
6.3 US & Canada Bispecific Antibodies for Cancer Market Size by Country
6.3.1 US & Canada Bispecific Antibodies for Cancer Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Bispecific Antibodies for Cancer Sales by Country (2019-2030)
6.3.3 US & Canada Bispecific Antibodies for Cancer Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Bispecific Antibodies for Cancer Market Size by Type
7.1.1 Europe Bispecific Antibodies for Cancer Sales by Type (2019-2030)
7.1.2 Europe Bispecific Antibodies for Cancer Revenue by Type (2019-2030)
7.2 Europe Bispecific Antibodies for Cancer Market Size by Application
7.2.1 Europe Bispecific Antibodies for Cancer Sales by Application (2019-2030)
7.2.2 Europe Bispecific Antibodies for Cancer Revenue by Application (2019-2030)
7.3 Europe Bispecific Antibodies for Cancer Market Size by Country
7.3.1 Europe Bispecific Antibodies for Cancer Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Bispecific Antibodies for Cancer Sales by Country (2019-2030)
7.3.3 Europe Bispecific Antibodies for Cancer Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Bispecific Antibodies for Cancer Market Size
8.1.1 China Bispecific Antibodies for Cancer Sales (2019-2030)
8.1.2 China Bispecific Antibodies for Cancer Revenue (2019-2030)
8.2 China Bispecific Antibodies for Cancer Market Size by Application
8.2.1 China Bispecific Antibodies for Cancer Sales by Application (2019-2030)
8.2.2 China Bispecific Antibodies for Cancer Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Bispecific Antibodies for Cancer Market Size by Type
9.1.1 Asia Bispecific Antibodies for Cancer Sales by Type (2019-2030)
9.1.2 Asia Bispecific Antibodies for Cancer Revenue by Type (2019-2030)
9.2 Asia Bispecific Antibodies for Cancer Market Size by Application
9.2.1 Asia Bispecific Antibodies for Cancer Sales by Application (2019-2030)
9.2.2 Asia Bispecific Antibodies for Cancer Revenue by Application (2019-2030)
9.3 Asia Bispecific Antibodies for Cancer Sales by Region
9.3.1 Asia Bispecific Antibodies for Cancer Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Bispecific Antibodies for Cancer Revenue by Region (2019-2030)
9.3.3 Asia Bispecific Antibodies for Cancer Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Bispecific Antibodies for Cancer Market Size by Type
10.1.1 Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Bispecific Antibodies for Cancer Market Size by Application
10.2.1 Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales by Country
10.3.1 Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Company Information
11.1.2 Amgen Overview
11.1.3 Amgen Bispecific Antibodies for Cancer Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Amgen Bispecific Antibodies for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Amgen Recent Developments
11.2 Astella Pharma
11.2.1 Astella Pharma Company Information
11.2.2 Astella Pharma Overview
11.2.3 Astella Pharma Bispecific Antibodies for Cancer Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Astella Pharma Bispecific Antibodies for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Astella Pharma Recent Developments
11.3 Ben Kang Biopharmaceutical (Shenzhen)
11.3.1 Ben Kang Biopharmaceutical (Shenzhen) Company Information
11.3.2 Ben Kang Biopharmaceutical (Shenzhen) Overview
11.3.3 Ben Kang Biopharmaceutical (Shenzhen) Bispecific Antibodies for Cancer Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Ben Kang Biopharmaceutical (Shenzhen) Bispecific Antibodies for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Ben Kang Biopharmaceutical (Shenzhen) Recent Developments
11.4 Merus
11.4.1 Merus Company Information
11.4.2 Merus Overview
11.4.3 Merus Bispecific Antibodies for Cancer Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Merus Bispecific Antibodies for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Merus Recent Developments
11.5 Regeneron Pharmaceuticals
11.5.1 Regeneron Pharmaceuticals Company Information
11.5.2 Regeneron Pharmaceuticals Overview
11.5.3 Regeneron Pharmaceuticals Bispecific Antibodies for Cancer Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Regeneron Pharmaceuticals Bispecific Antibodies for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Regeneron Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Bispecific Antibodies for Cancer Industry Chain Analysis
12.2 Bispecific Antibodies for Cancer Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Bispecific Antibodies for Cancer Production Mode & Process
12.4 Bispecific Antibodies for Cancer Sales and Marketing
12.4.1 Bispecific Antibodies for Cancer Sales Channels
12.4.2 Bispecific Antibodies for Cancer Distributors
12.5 Bispecific Antibodies for Cancer Customers
13 Market Dynamics
13.1 Bispecific Antibodies for Cancer Industry Trends
13.2 Bispecific Antibodies for Cancer Market Drivers
13.3 Bispecific Antibodies for Cancer Market Challenges
13.4 Bispecific Antibodies for Cancer Market Restraints
14 Key Findings in The Global Bispecific Antibodies for Cancer Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
FEATURED COMPANIES
Amgen Inc
Astella Pharma
Ben Kang Biopharmaceutical (Shenzhen)
Merus NV
Regeneron Pharmaceuticals
List of Tables
    Table 1. Global Bispecific Antibodies for Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Table 2. Major Manufacturers of CD19/CD3
    Table 3. Major Manufacturers of CD30/CD16A
    Table 4. Global Bispecific Antibodies for Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Table 5. Global Bispecific Antibodies for Cancer Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 6. Global Bispecific Antibodies for Cancer Revenue by Region (2019-2024) & (US$ Million)
    Table 7. Global Bispecific Antibodies for Cancer Revenue by Region (2025-2030) & (US$ Million)
    Table 8. Global Bispecific Antibodies for Cancer Revenue Market Share by Region (2019-2024)
    Table 9. Global Bispecific Antibodies for Cancer Revenue Market Share by Region (2025-2030)
    Table 10. Global Bispecific Antibodies for Cancer Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 11. Global Bispecific Antibodies for Cancer Sales by Region (2019-2024) & (K Units)
    Table 12. Global Bispecific Antibodies for Cancer Sales by Region (2025-2030) & (K Units)
    Table 13. Global Bispecific Antibodies for Cancer Sales Market Share by Region (2019-2024)
    Table 14. Global Bispecific Antibodies for Cancer Sales Market Share by Region (2025-2030)
    Table 15. Global Bispecific Antibodies for Cancer Sales by Manufacturers (2019-2024) & (K Units)
    Table 16. Global Bispecific Antibodies for Cancer Sales Share by Manufacturers (2019-2024)
    Table 17. Global Bispecific Antibodies for Cancer Revenue by Manufacturers (2019-2024) & (US$ Million)
    Table 18. Global Bispecific Antibodies for Cancer Revenue Share by Manufacturers (2019-2024)
    Table 19. Global Key Players of Bispecific Antibodies for Cancer, Industry Ranking, 2022 VS 2023 VS 2024
    Table 20. Bispecific Antibodies for Cancer Price by Manufacturers 2019-2024 (USD/Unit)
    Table 21. Global Bispecific Antibodies for Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Bispecific Antibodies for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bispecific Antibodies for Cancer as of 2023)
    Table 23. Global Key Manufacturers of Bispecific Antibodies for Cancer, Manufacturing Base Distribution and Headquarters
    Table 24. Global Key Manufacturers of Bispecific Antibodies for Cancer, Product Offered and Application
    Table 25. Global Key Manufacturers of Bispecific Antibodies for Cancer, Date of Enter into This Industry
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Bispecific Antibodies for Cancer Sales by Type (2019-2024) & (K Units)
    Table 28. Global Bispecific Antibodies for Cancer Sales by Type (2025-2030) & (K Units)
    Table 29. Global Bispecific Antibodies for Cancer Sales Share by Type (2019-2024)
    Table 30. Global Bispecific Antibodies for Cancer Sales Share by Type (2025-2030)
    Table 31. Global Bispecific Antibodies for Cancer Revenue by Type (2019-2024) & (US$ Million)
    Table 32. Global Bispecific Antibodies for Cancer Revenue by Type (2025-2030) & (US$ Million)
    Table 33. Global Bispecific Antibodies for Cancer Revenue Share by Type (2019-2024)
    Table 34. Global Bispecific Antibodies for Cancer Revenue Share by Type (2025-2030)
    Table 35. Bispecific Antibodies for Cancer Price by Type (2019-2024) & (USD/Unit)
    Table 36. Global Bispecific Antibodies for Cancer Price Forecast by Type (2025-2030) & (USD/Unit)
    Table 37. Global Bispecific Antibodies for Cancer Sales by Application (2019-2024) & (K Units)
    Table 38. Global Bispecific Antibodies for Cancer Sales by Application (2025-2030) & (K Units)
    Table 39. Global Bispecific Antibodies for Cancer Sales Share by Application (2019-2024)
    Table 40. Global Bispecific Antibodies for Cancer Sales Share by Application (2025-2030)
    Table 41. Global Bispecific Antibodies for Cancer Revenue by Application (2019-2024) & (US$ Million)
    Table 42. Global Bispecific Antibodies for Cancer Revenue by Application (2025-2030) & (US$ Million)
    Table 43. Global Bispecific Antibodies for Cancer Revenue Share by Application (2019-2024)
    Table 44. Global Bispecific Antibodies for Cancer Revenue Share by Application (2025-2030)
    Table 45. Bispecific Antibodies for Cancer Price by Application (2019-2024) & (USD/Unit)
    Table 46. Global Bispecific Antibodies for Cancer Price Forecast by Application (2025-2030) & (USD/Unit)
    Table 47. US & Canada Bispecific Antibodies for Cancer Sales by Type (2019-2024) & (K Units)
    Table 48. US & Canada Bispecific Antibodies for Cancer Sales by Type (2025-2030) & (K Units)
    Table 49. US & Canada Bispecific Antibodies for Cancer Revenue by Type (2019-2024) & (US$ Million)
    Table 50. US & Canada Bispecific Antibodies for Cancer Revenue by Type (2025-2030) & (US$ Million)
    Table 51. US & Canada Bispecific Antibodies for Cancer Sales by Application (2019-2024) & (K Units)
    Table 52. US & Canada Bispecific Antibodies for Cancer Sales by Application (2025-2030) & (K Units)
    Table 53. US & Canada Bispecific Antibodies for Cancer Revenue by Application (2019-2024) & (US$ Million)
    Table 54. US & Canada Bispecific Antibodies for Cancer Revenue by Application (2025-2030) & (US$ Million)
    Table 55. US & Canada Bispecific Antibodies for Cancer Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 56. US & Canada Bispecific Antibodies for Cancer Revenue by Country (2019-2024) & (US$ Million)
    Table 57. US & Canada Bispecific Antibodies for Cancer Revenue by Country (2025-2030) & (US$ Million)
    Table 58. US & Canada Bispecific Antibodies for Cancer Sales by Country (2019-2024) & (K Units)
    Table 59. US & Canada Bispecific Antibodies for Cancer Sales by Country (2025-2030) & (K Units)
    Table 60. Europe Bispecific Antibodies for Cancer Sales by Type (2019-2024) & (K Units)
    Table 61. Europe Bispecific Antibodies for Cancer Sales by Type (2025-2030) & (K Units)
    Table 62. Europe Bispecific Antibodies for Cancer Revenue by Type (2019-2024) & (US$ Million)
    Table 63. Europe Bispecific Antibodies for Cancer Revenue by Type (2025-2030) & (US$ Million)
    Table 64. Europe Bispecific Antibodies for Cancer Sales by Application (2019-2024) & (K Units)
    Table 65. Europe Bispecific Antibodies for Cancer Sales by Application (2025-2030) & (K Units)
    Table 66. Europe Bispecific Antibodies for Cancer Revenue by Application (2019-2024) & (US$ Million)
    Table 67. Europe Bispecific Antibodies for Cancer Revenue by Application (2025-2030) & (US$ Million)
    Table 68. Europe Bispecific Antibodies for Cancer Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 69. Europe Bispecific Antibodies for Cancer Revenue by Country (2019-2024) & (US$ Million)
    Table 70. Europe Bispecific Antibodies for Cancer Revenue by Country (2025-2030) & (US$ Million)
    Table 71. Europe Bispecific Antibodies for Cancer Sales by Country (2019-2024) & (K Units)
    Table 72. Europe Bispecific Antibodies for Cancer Sales by Country (2025-2030) & (K Units)
    Table 73. China Bispecific Antibodies for Cancer Sales by Type (2019-2024) & (K Units)
    Table 74. China Bispecific Antibodies for Cancer Sales by Type (2025-2030) & (K Units)
    Table 75. China Bispecific Antibodies for Cancer Revenue by Type (2019-2024) & (US$ Million)
    Table 76. China Bispecific Antibodies for Cancer Revenue by Type (2025-2030) & (US$ Million)
    Table 77. China Bispecific Antibodies for Cancer Sales by Application (2019-2024) & (K Units)
    Table 78. China Bispecific Antibodies for Cancer Sales by Application (2025-2030) & (K Units)
    Table 79. China Bispecific Antibodies for Cancer Revenue by Application (2019-2024) & (US$ Million)
    Table 80. China Bispecific Antibodies for Cancer Revenue by Application (2025-2030) & (US$ Million)
    Table 81. Asia Bispecific Antibodies for Cancer Sales by Type (2019-2024) & (K Units)
    Table 82. Asia Bispecific Antibodies for Cancer Sales by Type (2025-2030) & (K Units)
    Table 83. Asia Bispecific Antibodies for Cancer Revenue by Type (2019-2024) & (US$ Million)
    Table 84. Asia Bispecific Antibodies for Cancer Revenue by Type (2025-2030) & (US$ Million)
    Table 85. Asia Bispecific Antibodies for Cancer Sales by Application (2019-2024) & (K Units)
    Table 86. Asia Bispecific Antibodies for Cancer Sales by Application (2025-2030) & (K Units)
    Table 87. Asia Bispecific Antibodies for Cancer Revenue by Application (2019-2024) & (US$ Million)
    Table 88. Asia Bispecific Antibodies for Cancer Revenue by Application (2025-2030) & (US$ Million)
    Table 89. Asia Bispecific Antibodies for Cancer Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 90. Asia Bispecific Antibodies for Cancer Revenue by Region (2019-2024) & (US$ Million)
    Table 91. Asia Bispecific Antibodies for Cancer Revenue by Region (2025-2030) & (US$ Million)
    Table 92. Asia Bispecific Antibodies for Cancer Sales by Region (2019-2024) & (K Units)
    Table 93. Asia Bispecific Antibodies for Cancer Sales by Region (2025-2030) & (K Units)
    Table 94. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales by Type (2019-2024) & (K Units)
    Table 95. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales by Type (2025-2030) & (K Units)
    Table 96. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue by Type (2019-2024) & (US$ Million)
    Table 97. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue by Type (2025-2030) & (US$ Million)
    Table 98. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales by Application (2019-2024) & (K Units)
    Table 99. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales by Application (2025-2030) & (K Units)
    Table 100. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue by Application (2019-2024) & (US$ Million)
    Table 101. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue by Application (2025-2030) & (US$ Million)
    Table 102. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 103. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue by Country (2019-2024) & (US$ Million)
    Table 104. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue by Country (2025-2030) & (US$ Million)
    Table 105. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales by Country (2019-2024) & (K Units)
    Table 106. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales by Country (2025-2030) & (K Units)
    Table 107. Amgen Company Information
    Table 108. Amgen Description and Major Businesses
    Table 109. Amgen Bispecific Antibodies for Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 110. Amgen Bispecific Antibodies for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. Amgen Recent Developments
    Table 112. Astella Pharma Company Information
    Table 113. Astella Pharma Description and Major Businesses
    Table 114. Astella Pharma Bispecific Antibodies for Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 115. Astella Pharma Bispecific Antibodies for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. Astella Pharma Recent Developments
    Table 117. Ben Kang Biopharmaceutical (Shenzhen) Company Information
    Table 118. Ben Kang Biopharmaceutical (Shenzhen) Description and Major Businesses
    Table 119. Ben Kang Biopharmaceutical (Shenzhen) Bispecific Antibodies for Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 120. Ben Kang Biopharmaceutical (Shenzhen) Bispecific Antibodies for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
    Table 121. Ben Kang Biopharmaceutical (Shenzhen) Recent Developments
    Table 122. Merus Company Information
    Table 123. Merus Description and Major Businesses
    Table 124. Merus Bispecific Antibodies for Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 125. Merus Bispecific Antibodies for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
    Table 126. Merus Recent Developments
    Table 127. Regeneron Pharmaceuticals Company Information
    Table 128. Regeneron Pharmaceuticals Description and Major Businesses
    Table 129. Regeneron Pharmaceuticals Bispecific Antibodies for Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 130. Regeneron Pharmaceuticals Bispecific Antibodies for Cancer Product Model Numbers, Pictures, Descriptions and Specifications
    Table 131. Regeneron Pharmaceuticals Recent Developments
    Table 132. Key Raw Materials Lists
    Table 133. Raw Materials Key Suppliers Lists
    Table 134. Bispecific Antibodies for Cancer Distributors List
    Table 135. Bispecific Antibodies for Cancer Customers List
    Table 136. Bispecific Antibodies for Cancer Market Trends
    Table 137. Bispecific Antibodies for Cancer Market Drivers
    Table 138. Bispecific Antibodies for Cancer Market Challenges
    Table 139. Bispecific Antibodies for Cancer Market Restraints
    Table 140. Research Programs/Design for This Report
    Table 141. Key Data Information from Secondary Sources
    Table 142. Key Data Information from Primary Sources
List of Figures
    Figure 1. Bispecific Antibodies for Cancer Product Picture
    Figure 2. Global Bispecific Antibodies for Cancer Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Bispecific Antibodies for Cancer Market Share by Type in 2023 & 2030
    Figure 4. CD19/CD3 Product Picture
    Figure 5. CD30/CD16A Product Picture
    Figure 6. Global Bispecific Antibodies for Cancer Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Bispecific Antibodies for Cancer Market Share by Application in 2023 & 2030
    Figure 8. Hospital
    Figure 9. Pharmaceutical Companies
    Figure 10. Other
    Figure 11. Bispecific Antibodies for Cancer Report Years Considered
    Figure 12. Global Bispecific Antibodies for Cancer Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Bispecific Antibodies for Cancer Revenue 2019-2030 (US$ Million)
    Figure 14. Global Bispecific Antibodies for Cancer Revenue Market Share by Region in Percentage: 2023 Versus 2030
    Figure 15. Global Bispecific Antibodies for Cancer Revenue Market Share by Region (2019-2030)
    Figure 16. Global Bispecific Antibodies for Cancer Sales 2019-2030 ((K Units)
    Figure 17. Global Bispecific Antibodies for Cancer Sales Market Share by Region (2019-2030)
    Figure 18. US & Canada Bispecific Antibodies for Cancer Sales YoY (2019-2030) & (K Units)
    Figure 19. US & Canada Bispecific Antibodies for Cancer Revenue YoY (2019-2030) & (US$ Million)
    Figure 20. Europe Bispecific Antibodies for Cancer Sales YoY (2019-2030) & (K Units)
    Figure 21. Europe Bispecific Antibodies for Cancer Revenue YoY (2019-2030) & (US$ Million)
    Figure 22. China Bispecific Antibodies for Cancer Sales YoY (2019-2030) & (K Units)
    Figure 23. China Bispecific Antibodies for Cancer Revenue YoY (2019-2030) & (US$ Million)
    Figure 24. Asia (excluding China) Bispecific Antibodies for Cancer Sales YoY (2019-2030) & (K Units)
    Figure 25. Asia (excluding China) Bispecific Antibodies for Cancer Revenue YoY (2019-2030) & (US$ Million)
    Figure 26. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales YoY (2019-2030) & (K Units)
    Figure 27. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue YoY (2019-2030) & (US$ Million)
    Figure 28. The Bispecific Antibodies for Cancer Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
    Figure 29. The Top 5 and 10 Largest Manufacturers of Bispecific Antibodies for Cancer in the World: Market Share by Bispecific Antibodies for Cancer Revenue in 2023
    Figure 30. Global Bispecific Antibodies for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 31. Global Bispecific Antibodies for Cancer Sales Market Share by Type (2019-2030)
    Figure 32. Global Bispecific Antibodies for Cancer Revenue Market Share by Type (2019-2030)
    Figure 33. Global Bispecific Antibodies for Cancer Sales Market Share by Application (2019-2030)
    Figure 34. Global Bispecific Antibodies for Cancer Revenue Market Share by Application (2019-2030)
    Figure 35. US & Canada Bispecific Antibodies for Cancer Sales Market Share by Type (2019-2030)
    Figure 36. US & Canada Bispecific Antibodies for Cancer Revenue Market Share by Type (2019-2030)
    Figure 37. US & Canada Bispecific Antibodies for Cancer Sales Market Share by Application (2019-2030)
    Figure 38. US & Canada Bispecific Antibodies for Cancer Revenue Market Share by Application (2019-2030)
    Figure 39. US & Canada Bispecific Antibodies for Cancer Revenue Share by Country (2019-2030)
    Figure 40. US & Canada Bispecific Antibodies for Cancer Sales Share by Country (2019-2030)
    Figure 41. U.S. Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 42. Canada Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 43. Europe Bispecific Antibodies for Cancer Sales Market Share by Type (2019-2030)
    Figure 44. Europe Bispecific Antibodies for Cancer Revenue Market Share by Type (2019-2030)
    Figure 45. Europe Bispecific Antibodies for Cancer Sales Market Share by Application (2019-2030)
    Figure 46. Europe Bispecific Antibodies for Cancer Revenue Market Share by Application (2019-2030)
    Figure 47. Europe Bispecific Antibodies for Cancer Revenue Share by Country (2019-2030)
    Figure 48. Europe Bispecific Antibodies for Cancer Sales Share by Country (2019-2030)
    Figure 49. Germany Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 50. France Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 51. U.K. Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 52. Italy Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 53. Russia Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 54. China Bispecific Antibodies for Cancer Sales Market Share by Type (2019-2030)
    Figure 55. China Bispecific Antibodies for Cancer Revenue Market Share by Type (2019-2030)
    Figure 56. China Bispecific Antibodies for Cancer Sales Market Share by Application (2019-2030)
    Figure 57. China Bispecific Antibodies for Cancer Revenue Market Share by Application (2019-2030)
    Figure 58. Asia Bispecific Antibodies for Cancer Sales Market Share by Type (2019-2030)
    Figure 59. Asia Bispecific Antibodies for Cancer Revenue Market Share by Type (2019-2030)
    Figure 60. Asia Bispecific Antibodies for Cancer Sales Market Share by Application (2019-2030)
    Figure 61. Asia Bispecific Antibodies for Cancer Revenue Market Share by Application (2019-2030)
    Figure 62. Asia Bispecific Antibodies for Cancer Revenue Share by Region (2019-2030)
    Figure 63. Asia Bispecific Antibodies for Cancer Sales Share by Region (2019-2030)
    Figure 64. Japan Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 65. South Korea Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 66. China Taiwan Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 67. Southeast Asia Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 68. India Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 69. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales Market Share by Type (2019-2030)
    Figure 70. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue Market Share by Type (2019-2030)
    Figure 71. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales Market Share by Application (2019-2030)
    Figure 72. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue Market Share by Application (2019-2030)
    Figure 73. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Revenue Share by Country (2019-2030)
    Figure 74. Middle East, Africa and Latin America Bispecific Antibodies for Cancer Sales Share by Country (2019-2030)
    Figure 75. Brazil Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 76. Mexico Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 77. Turkey Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 78. Israel Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 79. GCC Countries Bispecific Antibodies for Cancer Revenue (2019-2030) & (US$ Million)
    Figure 80. Bispecific Antibodies for Cancer Value Chain
    Figure 81. Bispecific Antibodies for Cancer Production Process
    Figure 82. Channels of Distribution
    Figure 83. Distributors Profiles
    Figure 84. Bottom-up and Top-down Approaches for This Report
    Figure 85. Data Triangulation
    Figure 86. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Primary Biliary Cholangitis Therapeutics Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-11W14373
Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Hurthle Cell Carcinoma Treatment Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-35B1140
Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Anaplastic Large Cell Lymphoma Drugs Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-27H888
Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Anaplastic Large Cell Lymphoma Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-16R5994
Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions